Jupiter Topco LLC Invests $95.27 Million in BioCryst Pharmaceuticals, Inc. $BCRX

Jupiter Topco LLC purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,540,764 shares of the biotechnology company’s stock, valued at approximately $95,268,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at $238,930,000. RA Capital Management L.P. purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth $123,452,000. Deerfield Management Company L.P. boosted its position in shares of BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after acquiring an additional 7,477,000 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of BioCryst Pharmaceuticals by 7,807.2% during the 4th quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock valued at $57,791,000 after acquiring an additional 7,310,745 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its position in shares of BioCryst Pharmaceuticals by 135.1% during the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after acquiring an additional 4,271,504 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $9.83 on Thursday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.22. The firm has a market cap of $2.51 billion, a PE ratio of -6.55 and a beta of 0.55. The company has a 50-day moving average of $9.68 and a two-hundred day moving average of $9.02.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The business had revenue of $218.25 million for the quarter, compared to the consensus estimate of $183.28 million. During the same period in the previous year, the firm earned $0.15 EPS. The business’s revenue was up 33.6% on a year-over-year basis. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. Needham & Company LLC dropped their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. JPMorgan Chase & Co. assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Monday, July 13th. They set a “neutral” rating and a $12.00 price target on the stock. Finally, Citizens Jmp upped their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.